Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsBMKDF 24 3-Year EBITDA Growth Rate is 14.50% as of Jun. 2026, which is 625% above its 10-year median of 2.00. GuruFocus rates BMKDF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Biomark Diagnostics ranks better than 53.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 2.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biomark Diagnostics was 52.50% per year. The lowest was -26.00% per year. And the median was 2.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biomark Diagnostics 3-Year EBITDA Growth Rate Related Terms
BMKDF vs TMO, DHR, NTRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Biomark Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.50% mean?
Biomark Diagnostics (BMKDF) has a 3-Year EBITDA Growth Rate of 14.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biomark Diagnostics and its competitors. This is 625% above median its historical median of 2.00. According to the industry distribution chart, Biomark Diagnostics ranks #77 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 46.1%.
Is Biomark Diagnostics' 3-Year EBITDA Growth Rate too high?
Biomark Diagnostics' current 3-Year EBITDA Growth Rate of 14.50% is 625% above median its 10-year median of 2.00. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.60. Biomark Diagnostics' value of 14.50% is 36.8% above this industry median. Based on the distribution chart, Biomark Diagnostics ranks #77 out of 167 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Biomark Diagnostics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #77 out of 167 companies for 3-Year EBITDA Growth Rate. This puts Biomark Diagnostics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.60. Biomark Diagnostics' value of 14.50% is 36.8% above this benchmark. While the company's 10-year median is 2.00 vs. the industry median of 10.60, Biomark Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.60, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomark Diagnostics's current 3-Year EBITDA Growth Rate of 14.50% is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current 3-Year EBITDA Growth Rate is 14.50%, which is 625% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (BMKDF) has a current 3-Year EBITDA Growth Rate of 14.50%. The current 3-Year EBITDA Growth Rate is 14.50%, which is 625% above median its 10-year median of 2.00 and 36.8% above the Medical Diagnostics & Research industry median of 10.60. Biomark Diagnostics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biomark Diagnostics (BMKDF), the current 3-Year EBITDA Growth Rate is 14.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
24GF Score
Get the complete analysis for BMKDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMKDF has been successfully added to your 
